Federal Rule Risks Permanent Nonscientific Control Over Science Despite Grant Restorations

The federal government’s abrupt termination of research grants in 2023 has left lasting damage to U.S. biomedical science, with scientists warning that even restored funding cannot fully reverse the disruption. A proposed rule now threatens to institutionalize political interference in scientific decision-making, according to researchers and advocacy groups.

Federal agencies including the National Institutes of Health (NIH) and National Science Foundation (NSF) canceled or delayed hundreds of grants between 2022 and 2023, citing budget constraints and shifting priorities. While some grants have been reinstated—NIH restored $3.2 billion in funding in June 2024—experts say the administrative chaos, lost momentum in labs, and diverted researcher time have created irreversible setbacks. A 2024 survey of 1,200 principal investigators by the Association of American Universities found that 68% reported delays in critical experiments, while 42% cited grant terminations as a reason for pausing or scaling back research entirely.

The deeper concern, however, is a proposed rule from the Office of Management and Budget (OMB) that would require federal agencies to justify scientific funding decisions based on “broader societal impact” rather than peer-reviewed merit alone. Critics argue this opens the door for nonscientific influences—such as political appointees or industry lobbying—to override the traditional expert-driven process. The rule, still under review, has drawn sharp opposition from academic institutions and scientific societies, including the American Association for the Advancement of Science (AAAS), which called it a “fundamental threat to evidence-based policymaking.”

Why did the grant terminations happen—and who was most affected?
The mass cancellations began in late 2022, when the Biden administration froze discretionary spending amid broader fiscal uncertainty. NIH Director Monica Bertagnolli told Congress in March 2023 that 15% of active grants faced delays or reductions, disproportionately affecting early-career researchers and labs studying long-term conditions like Alzheimer’s or chronic pain. A 2024 analysis in Science found that grants in basic science fields—where funding cycles are longer—were 2.3 times more likely to be terminated than applied or clinical research grants.

The impact extended beyond individual labs. Universities reported layoffs of administrative staff supporting grant applications, while postdoctoral fellows and graduate students faced uncertain futures. At the University of California, San Francisco, for example, the School of Medicine announced a hiring freeze for 18 months after grant cuts forced a 10% reduction in lab budgets. “Some projects were paused mid-experiment,” said Dr. Elena Rodriguez, a neuroscientist at UCSF whose lab studies Parkinson’s disease. “We had to euthanize animal subjects in the middle of a critical phase because we couldn’t replace them.”

How does the proposed OMB rule change scientific funding—and what’s the risk?
The OMB’s draft guidance, leaked to The Scientist in May 2026, would require agencies to evaluate grants not just on scientific rigor but also on “alignment with national priorities” as defined by the executive branch. While the rule does not explicitly ban peer review, it mandates that agencies document how funding decisions consider “diverse perspectives” and “equitable outcomes”—language that researchers interpret as a pathway for political influence.

The AAAS warned in a June 2026 letter to OMB Director Shalanda Young that the rule could lead to “arbitrary funding decisions” by shifting authority from independent review panels to agency officials. “This is not about merit,” said Dr. Harold Varmus, a Nobel laureate and former NIH director. “It’s about control.” The rule also raises concerns about transparency: agencies would not be required to disclose the criteria used to override peer-review recommendations.

What’s next for scientific funding—and what could go wrong?
Congressional hearings in July 2026 revealed bipartisan unease over the OMB proposal. Senators Elizabeth Warren (D-Mass.) and Rand Paul (R-Ky.) both questioned whether the rule would politicize science, with Paul calling it “a recipe for corruption.” The NIH and NSF have not yet committed to adopting the guidance, but agencies face deadlines to comply with OMB directives by January 2027.

Researchers fear the rule could discourage high-risk, high-reward science—the kind that often leads to breakthroughs. A 2025 study in PNAS found that grants in “transformative” research categories (those with the potential for major advances) declined by 18% in the year after the 2022 funding freeze. “If agencies start prioritizing ‘safe’ research over bold ideas, we’ll see a generation of missed opportunities,” said Dr. Priya Sharma, a bioengineer at MIT who studies regenerative medicine.

The uncertainty has also accelerated a brain drain: a 2026 report from the Federation of American Societies for Experimental Biology found that 34% of U.S.-trained scientists now consider leaving the country for more stable funding environments. Canada, Germany, and the UK have seen increased applications from American researchers in fields like immunology and genomics.

How are other countries handling scientific funding—and what can the U.S. learn?
While the U.S. grapples with political interference, other nations have maintained more consistent funding models. In Germany, the Deutsche Forschungsgemeinschaft (DFG) operates under a strict peer-review system with minimal government oversight, leading to a 92% approval rate for grants—far higher than the U.S. average of 65%. The UK’s Medical Research Council, meanwhile, has faced its own budget pressures but has avoided mass cancellations by redistributing funds internally rather than terminating grants outright.

Experts point to two key differences: transparency and stability. “In the U.S., funding is often treated as a political football,” said Dr. David Baltimore, a former NIH director. “Other countries treat it as an investment in long-term innovation.” The OMB rule, if finalized, could deepen that instability by making funding decisions even more unpredictable.

What researchers are saying—and what you should watch for
Scientists contacted by Medscape Medical News emphasized that the damage from the grant terminations is already visible. “Some labs will never recover,” said Dr. Rodriguez at UCSF. “Even if funding is restored, the talent pipeline has been disrupted.” Others warned that the OMB rule could have broader consequences, including:

• A decline in interdisciplinary research, as agencies may favor projects aligned with narrow political agendas.
• Increased reliance on private funding, which could further skew research toward industry priorities.
• Longer review cycles, as agencies add new layers of bureaucratic scrutiny to justify funding decisions.

The next critical date is October 2026, when the OMB is expected to finalize the rule. If adopted, agencies will have until early 2027 to implement it—giving researchers less than a year to adapt. “This is not just about money,” said Dr. Sharma. “It’s about whether science in America will still be trusted.”

Key sources and further reading

• Association of American Universities (2024). Impact of Grant Delays on Biomedical Research.
• Science (2024). “Disproportionate Effects of Funding Cuts on Basic Research.”
• American Association for the Advancement of Science (2026). Letter to OMB on Proposed Funding Rule.
• PNAS (2025). “The Chilling Effect of Uncertainty on High-Risk Research.”
• Deutsche Forschungsgemeinschaft (DFG) (2026). Annual Grant Approval Report.